Evidence map›Paper›PMID 38464055›Full record

ArticlebioRxiv : the preprint server for biology2024

Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal.

William J Cisneros, Miriam Walter, Shimaa H A Soliman, Lacy M Simons, Daphne Cornish, Ariel W Halle, Eun-Young Kim, Steven M Wolinsky, Ali Shilatifard, Judd F Hultquist

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

William J CisnerosDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0003-2472-6167
Miriam WalterDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Shimaa H A SolimanSimpson Querrey Institute for Epigenetics, Department of Biochemistry and Molecular Genetics Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Lacy M SimonsDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Daphne CornishDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Ariel W HalleDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Eun-Young KimDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Steven M WolinskyDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Ali ShilatifardSimpson Querrey Institute for Epigenetics, Department of Biochemistry and Molecular Genetics Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Judd F HultquistDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0001-6424-4280
Northwestern University · US

Funding

Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Sahera Dirajlal-Fargo · 2015 to 2026
$38.4M
Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$35.7M
CELLULAR &MOLECULAR BASIS OF DISEASE TRAINING PROGRAMT32GM008061 · NIGMS · NORTHWESTERN UNIVERSITY · PI CARTHEW, RICHARD W. · 1985 to 2022
$17.1M
Functionally Defining HIV-Host Interactions During the Early HIV-1 LifecycleR01AI150998 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIENIASZ, PAUL D., HOPE, THOMAS · 2020 to 2024
$6.8M
Turning off HIV White Noise: Switching from Long-Lived to Short-Lived ReservoirR01AI176599 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Elena Martinelli · 2023 to 2026
$4.7M
Regulation of SAMHD1 antiviral activityR01AI150455 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI DIAZ-GRIFFERO, FELIPE · 2019 to 2024
$3.3M
Deciphering the Role of CPSF6 in HIV InfectionR01AI165236 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F · 2021 to 2025
$2.0M
Controlling HIV latency by manipulating CycT1 turnoverR01AI167778 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FUJINAGA, KOH · 2022 to 2025
$1.6M
Donor-specific anti-HIV/SIV immunity mediated by APOBEC3 enzymesR56AI174877 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI EBRAHIMI, DIAKO · 2023 to 2023
$833k
Exploring Small Molecule Inhibitors of PAF1C as Novel HIV Latency Reversal AgentsR21AI174864 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F, SHILATIFARD, ALI · 2023 to 2024
$426k
NIAID NIH HHS P30 AI117943NIAID NIH HHS R01 AI150455NIAID NIH HHS R01 AI150998NIAID NIH HHS R01 AI165236NIAID NIH HHS R01 AI167778NIAID NIH HHS R01 AI176599NIAID NIH HHS R21 AI174864NIAID NIH HHS R56 AI174877NIAID NIH HHS U54 AI170792NIGMS NIH HHS T32 GM008061
6 · The paper itself

Abstract

The persistence of HIV-1 in long-lived latent reservoirs during suppressive antiretroviral therapy (ART) remains one of the principal barriers to a functional cure. Blocks to transcriptional elongation play a central role in maintaining the latent state, and several latency reversal strategies focus on the release of positive transcription elongation factor b (P-TEFb) from sequestration by negative regulatory complexes, such as the 7SK complex and BRD4. Another major cellular reservoir of P-TEFb is in Super Elongation Complexes (SECs), which play broad regulatory roles in host gene expression. Still, it is unknown if the release of P-TEFb from SECs is a viable latency reversal strategy. Here, we demonstrate that the SEC is not required for HIV-1 replication in primary CD4+ T cells and that a small molecular inhibitor of the P-TEFb/SEC interaction (termed KL-2) increases viral transcription. KL-2 acts synergistically with other latency reversing agents (LRAs) to reactivate viral transcription in several cell line models of latency in a manner that is, at least in part, dependent on the viral Tat protein. Finally, we demonstrate that KL-2 enhances viral reactivation in peripheral blood mononuclear cells (PBMCs) from people living with HIV on suppressive ART, most notably in combination with inhibitor of apoptosis protein antagonists (IAPi). Taken together, these results suggest that the release of P-TEFb from cellular SECs may be a novel route for HIV-1 latency reactivation.

Indexed as

HIV-1KL-2LatencyLatency Reversing AgentP-TEFbSuper Elongation ComplexTranscriptional Elongation

Identifiers

PMID38464055
PMCPMC10925308
OpenAlexW4392350791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.